<DOC>
	<DOCNO>NCT02227277</DOCNO>
	<brief_summary>The purpose study determine treatment pegylated interferon alpha 2b ( peg-IFN-α2b ) reduce amount integrate HIV DNA peripheral blood cell tissues individual chronic HIV infection receive antiretroviral treatment ( ART ) . A reduction and/or clearance latent viral reservoir ( i.e . : virus remain dormant HIV-infected subject receive suppressive treatment ) consider essential HIV eradication . By measure change integrate proviral HIV DNA , consider surrogate measure latent reservoir , investigator establish peg-IFN-α2b treatment consider component future viral eradication strategy .</brief_summary>
	<brief_title>Reducing Proviral HIV DNA With Interferon-a</brief_title>
	<detailed_description>Our long-term goal evaluate effect pegylated interferon ( peg-IFN ) α anti-HIV reservoir immunotherapy could potentiate eradication strategy HIV . The present study 3-arm randomized clinical trial ( RCT ) . The aim study determine whether 20-week treatment course 1μg/kg/week pegylated interferon alpha 2 b ( peg-IFN-α2b ) reduce level HIV-1 proviral DNA level circulate PBMC mucosa-associated lymphoid tissue ( MALT ) HIV-infected individual receive long-term ART . In addition , study 4-week interruption ART necessary observe change proviral DNA level . In previous study ( NCT00594880 ) different form Interferon alpha ( peg-IFN-α2a ) , observed reduction proviral DNA peripheral blood cell 50 % patient . However , measure level MALT , could determine whether interruption ART necessary . The present study address question . We also seek determine biological mechanism ( increase Natural Killer cell cytotoxicity ) mediate antiviral effect peg-IFN-α .</detailed_description>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Inclusion criterion 1865 year age Body weight ≥ 125 ≤ 300 lb Confirmed diagnosis HIV1 infection western blot document HIV1 viral load screening . Currently receive ART ART ≥ 1 year VL &lt; 50 copies/ml ≥ 1 year , least 2 measurement previous year . 1 viral `` blip '' VL &lt; 400 copies/ml allow 1 measurement &lt; 50 copies/ml available 3 month 3 month `` blip '' without change ART HIV viral load &lt; 50 copies/ml screening . CD4 &gt; 450 cells/µL screening . negative electrocardiogram ( EKG , see section 7.4 ) : ) men &gt; 45 year woman &gt; 55 year age b ) young subject either sex two risk factor coronary artery disease [ smoking , hypertension ( BP &gt; 140/90 antihypertensive medication ) , low HDL ( &lt; 40 mg/dl ) , family history premature CHD ( &lt; 55 yr males/ &lt; 65 female , c ) subject Framingham score &gt; 15 % ( men ) 10 % ( woman ) Exclusion criterion Current prior medication Confirmed clinical history develop resistance ART regimens result treatment change Receiving didanosine part participant 's ART regimen time screen Ongoing treatment Isoniazid , Pyrazinamide , Rifabutin , Rifampicin , Ganciclovir , Valgancyclovir , Oxymetholone , Thalidomide Theophylline . Ongoing treatment anticoagulant Use investigational drug within 30 day prior screen History current use immunomodulatory therapy 2 week 6 month prior enrollment , include , limited : IFNα γ ( recombinant pegylated ) , systemic corticosteroid ( inhaled steroid allow discretion Investigator ) ; systemic cancer chemotherapy/irradiation ; cyclosporin ; tacrolimus ( FK506 ) ; OKT3 ; Interleukin , include IL2 ; cyclophosphamide ; methotrexate ; IVIG ( gamma globulin ) ; G/MCSF ; hydroxyurea ; thalidomide ; pentoxifylline ; thymopentin ; thymosin ; dithiocarbonate ; polyribonucloside . History adverse allergic reaction type1 interferon ( e.g . IFNα2a , IFNα2b , IFNβ ) Current prior clinical condition History severe depression , include history suicidal ideation attempt , ongoing moderate depression determine PHQ9 screen Type I diabetes mellitus , type II diabetes mellitus control oral agent and/or insulin ( i.e . : subject history diabetes mellitus HA1C &gt; 9 last 3 month screen ) . Prior diagnosis multiple sclerosis neurodegenerative disorder Significant coexist lab abnormality include : ) Anemia ( Hgb &lt; 9.1 mg/dl men , &lt; 8.9 mg/dl woman ) ; b ) Ongoing coagulopathy/clotting disorder ; c ) WBC &lt; 2000 cells/µl ; ) Absolute neutrophil count ( ANC ) &lt; 1200 cells/ µl ; e ) Platelet count &lt; 60,000 cells/ µl ; f ) Liver disease ( AST/ALT &gt; 2.5x OR total bilirubin &gt; 1.5x upper limit norm ( ULN ) , ( receive atazanavir ) direct bilirubin &gt; 0.6 ( receive atazanavir ) ; g ) Pancreatic disease ( amylase : &gt; 1.5 ULN , lipase &gt; 1.5 ULN , triglycerides &gt; 750 mg/dl ) ; h Renal disease ( creatinine &gt; 2x ULN creatinine clearance &lt; 60mg/dl ( CrockoffGault ) Chronic HCV infection ( HCV viremia ) , HBV Ag positive and/ HBV viremia ( Notice : subject prior HCV infection document sustained virologic response treatment finish &gt; 1 year prior screen eligible enrollment ) . Liver cirrhosis hepatic decompensation Child Pugh score &gt; 6 History major organ transplantation exist functional graft . Evidence OI active infectious disease active malignancy Active Autoimmune disease , include autoimmune hepatitis History retinopathy clinically significant ophthalmologic disease eye exam perform within 60 day prior initiation IFN Significant EKG abnormality ( see section 7.4 ) Other condition Pregnancy breastfeed A planned pregnancy study participation Lack one three strategy birth control study participation : ) Barrier contraceptive ( male female condom without spermicidal agent , diaphragm cervical cap spermicidal ) ; b ) Nonhormonal Intrauterine Devices ( IUDs ) ; c ) Hormonalbased , include hormonal IUDs , combination barrier contraceptive . Body weight &lt; 125 lbs &gt; 300 lb Other condition , active drug/alcohol abuse dependence , opinion Investigator would interfere study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Pegintron</keyword>
	<keyword>Peg-IFN-α2b</keyword>
	<keyword>Viral suppression</keyword>
	<keyword>ART cessation</keyword>
	<keyword>Immune function</keyword>
	<keyword>Innate immunity</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Immune-based therapy</keyword>
	<keyword>Treatment interruption</keyword>
	<keyword>HIV Cure</keyword>
	<keyword>HIV Eradication</keyword>
	<keyword>BEAT-HIV</keyword>
	<keyword>HIV Cure Trial</keyword>
	<keyword>Cure Trial</keyword>
</DOC>